Company intelligence / Profile preview

Burzynski Research Institute

Houston, Texas, United Statespropcitweb.ddns.net ↗

Ownership: Public · BZYR
Development stage: Other

Overview

Burzynski Research Institute is developing investigational cancer therapies called antineoplastons. These have been studied primarily in phase I and II trials for various cancers, especially malignant brain tumors. A randomized phase III trial for diffuse intrinsic brainstem glioma is ongoing as of June 2025. However, there is no robust independent evidence supporting efficacy; most positive results come from within the organization itself. No FDA-approved products exist to date.

Therapeutic areas: Oncology
Modalities: Small moleculePeptides
Industry: Biotech

Drug pipeline

9 assets

antineoplaston A10

8 more assets in the full pipeline.

Request access →

Financials

Market cap: $262.9K
Total revenue: $0
Enterprise value: $260.7K

Beyond the preview

Go deeper on Burzynski Research Institute.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Burzynski Research Institute.

Explore the full profile